Skip to content
Preladenant
Preladenant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target adenosine receptor A3, adenosine receptor A1, adenosine receptor A2b, and adenosine receptor A2a.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G20234——9
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Movement disordersD009069EFO_0004280G25—3———3
Central nervous system diseasesD002493HP_0002011G96.9—2———2
Brain diseasesD001927HP_0001298G93.40—2———2
Neurodegenerative diseasesD019636EFO_0005772G31.9—2———2
Drug-induced akathisiaD017109EFO_1000903G25.71—2———2
Parkinsonian disordersD020734HP_0001300—1———1
Drug-induced dyskinesiaD004409EFO_1000904—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePRELADENANT
INNpreladenant
Description
Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson's disease. Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013.
Classification
Small molecule
Drug classadenosine receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COCCOc1ccc(N2CCN(CCn3ncc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)cc1
Identifiers
PDB—
CAS-ID377727-87-2
RxCUI—
ChEMBL IDCHEMBL240624
ChEBI ID—
PubChem CID10117987
DrugBankDB11864
UNII ID950O97NUPO (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ADORA3
ADORA3
ADORA1
ADORA1
ADORA2B
ADORA2B
ADORA2A
ADORA2A
Organism
Homo sapiens
Gene name
ADORA3
Gene synonyms
NCBI Gene ID
140
Protein name
adenosine receptor A3
Protein synonyms
Uniprot ID
Q9BYZ1
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 265 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details